Cargando…

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal biomarker analysis revealed that faecal calprotectin, C-reactive protein, serum or mucosal concentrations of anti-TNF monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Guanglin, Fan, Qingbo, Li, Zhenfeng, Goll, Rasmus, Florholmen, Jon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054158/ https://www.ncbi.nlm.nih.gov/pubmed/33862588 http://dx.doi.org/10.1016/j.ebiom.2021.103329

Ejemplares similares

Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?
por: Cui, Guanglin, et al.
Publicado: (2022)

ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis
por: Cui, Guanglin, et al.
Publicado: (2020)

Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR
por: Goll, Rasmus, et al.
Publicado: (2006)

Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis
por: Goll, Rasmus, et al.
Publicado: (2019)

Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
por: Goll, Rasmus, et al.
Publicado: (2022)

Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
por: Johnsen, Kay-Martin, et al.
Publicado: (2022)

Contribution of IL-33 to the Pathogenesis of Colorectal Cancer
por: Cui, Guanglin, et al.
Publicado: (2018)

Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis
por: Florholmen, Jon R., et al.
Publicado: (2020)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects
por: Isaksen, Victoria T., et al.
Publicado: (2016)

Ulcerative colitis: functional analysis of the in-depth proteome
por: Schniers, Armin, et al.
Publicado: (2019)

Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
por: Bek, S., et al.
Publicado: (2016)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Hypo-osmotic stress induces the epithelial alarmin IL-33 in the colonic barrier of ulcerative colitis
por: Gundersen, Mona Dixon, et al.
Publicado: (2022)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Mucosal Metabolomic Profiling and Pathway Analysis Reveal the Metabolic Signature of Ulcerative Colitis
por: Diab, Joseph, et al.
Publicado: (2019)

Real-life evaluation of histologic scores for Ulcerative Colitis in remission
por: Arkteg, Christian Børde, et al.
Publicado: (2021)

An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
por: Patel, Rajan N., et al.
Publicado: (2020)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Are We Ready for Proactive Therapeutic Drug Monitoring of Anti-TNF to Optimize Care of Patients With Inflammatory Bowel Disease?
por: Charabaty, Aline
Publicado: (2020)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
por: Aardoom, Martine A., et al.
Publicado: (2019)

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease
por: Alghoul, Zahra, et al.
Publicado: (2022)

Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis
por: Gundersen, Mona Dixon, et al.
Publicado: (2019)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease
por: Okuyucu, Muhammed, et al.
Publicado: (2022)

The microbiota in inflammatory bowel disease: current and therapeutic insights
por: Lane, Erin R, et al.
Publicado: (2017)

A Systematic Review of Epidemiology and Risk Factors Associated With Chinese Inflammatory Bowel Disease
por: Cui, Guanglin, et al.
Publicado: (2018)

DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis
por: Taman, Hagar, et al.
Publicado: (2021)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

The economic burden of TNFα inhibitors and other biologic treatments in Norway
por: Norum, Jan, et al.
Publicado: (2011)

Adherence to Subcutaneous Anti-TNF Treatment in Chronic Inflammatory Rheumatism and Therapeutic Patient Education
por: Fayet, Françoise, et al.
Publicado: (2020)

How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions
por: Eder, Piotr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3pjmc4t8icguf6le4st0vrbtvi